Name: Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: Co-prescribed/Concomitant therapies
Published: 2026-09-27T09:44:05-04:00

Product information and disease description Product description Product information

Co-prescribed/Concomitant therapies

6 evidence topics · 2 sources

Prior systemic therapy required before lirafugratinib

“All patients had received at least one prior line of platinum-based systemic therapy” (opens the prescribing information at this quote)

Ocular demulcents and lubricating eye products

“to use artificial tears or hydrating or lubricating eye gels to prevent or treat dry eyes [see Warnings and Precautions (5.1)].” (opens the prescribing information at this quote)

“Dry eye occurred in 38% of patients. Treat patients with ocular demulcents as needed.” (opens the source at this quote in a new tab)

Serum phosphate monitoring and phosphate management

“Monitor serum phosphate throughout treatment and manage as clinically appropriate.” (opens the source at this quote in a new tab)

“Phosphate binders were required in 7 (1.8%) patients who received LYRFIGTU.” (opens the prescribing information at this quote)
“Inform patients that LYRFIGTU may cause hyperphosphatemia and soft tissue mineralization and to immediately inform their healthcare provider of any symptoms related to acute change in phosphate levels such as muscle cramps, numbness, or tingling around the mouth” (opens the prescribing information at this quote)

Scheduled ophthalmologic examinations with optical coherence tomography

“Perform a comprehensive ophthalmological examination, including OCT of the macula, prior to initiation of therapy, every 2 months for the first 13 months, and every 4 months thereafter.” (opens the prescribing information at this quote)

Contraception and sun protection

“Advise males with female partners of reproductive potential to use effective contraception during treatment with LYRFIGTU and for 3 months after the last dose.” (opens the prescribing information at this quote)
“Inform patients that LYRFIGTU may cause phototoxicity and advise the use of sunscreen, protective clothing, and sunglasses, as well as minimizing sun exposure [see Nonclinical Toxicology (13.2)].” (opens the prescribing information at this quote)

Concomitant medications to avoid

“Advise patients to inform their healthcare providers of all concomitant medications, including prescription medicines, over-the-counter drugs, and herbal products.” (opens the prescribing information at this quote)